Eisai Acquires Four Oncology-Related Products from Ligand.Tokyo, Japan, Sept 8, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Eisai has announced that it signed a product acquisition agreement with California-based Ligand ligand (lĭg`ənd), charged or uncharged molecule with one or more unshared pairs of electrons that can attach to a central metallic atom or ion to form an aggregate known as a complex ion (see chemical bond). Pharmaceuticals for exclusive global rights for their four oncology-related products, ONTAK (denileukin diftitox denileukin diftitox /den·i·leu·kin dif·ti·tox/ (den?i-loo´kin dif´ti-toks) a genetically engineered construct combining amino acid sequences for specific diphtheria toxin fragments linked to sequences for interleukin-2 (IL-2); used as an ), Targretin (bexarotene bexarotene /bex·ar·o·tene/ (bek-sar´ah-ten) a retinoid used as an antineoplastic in the treatment of cutaneous T-cell lymphoma and the cutaneous lesions of T-cell lymphomas and Kaposi's sarcoma. ) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. The transaction is subject to governmental approvals and is expected to close after certain preparation period. Eisai will pay U.S. $205 million for the acquisition, and offer Ligand personnel employment by Eisai Inc. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion